Articles tagged with Vaccination
A novel protein vaccine candidate has demonstrated full protection against a lethal aerosol challenge with ricin toxin in mice, offering a promising solution to bioterrorism threats. The vaccine, RTA 1-33/44-198, was designed using molecular modeling and protein engineering techniques.
A survey of mothers reveals that they view pediatricians as 'parenting partners' and carefully select a doctor for their child. Key findings include the importance of personality, health insurance coverage, and compatibility with parenting objectives in choosing a pediatrician.
Researchers used glycan microarrays to explore novel immunologic targets for SARS-CoV. The study found undesired autoantibody reactivity against human serum glycoprotein ASOR, prompting concerns over the safety of whole-viral SARS vaccines.
A new breed of vaccine-producing plants is being developed to combat global health issues, including cholera and diarrhea. The innovative technology uses minimal processing to yield heat-stable vaccines for oral delivery.
Researchers will investigate the link between atopic dermatitis and severe skin reaction EV in a nationwide research network. The study aims to better understand how atopic dermatitis predisposes individuals to EV after smallpox vaccination.
OHSU researchers are studying vaccination methods for seniors and children, with a focus on developing protection against infectious diseases. The study aims to understand immune system changes that occur with aging and develop methods to manipulate the system for better protection.
Scientists at the University of Rochester Medical Center created an Alzheimer's vaccine with a customizable immune response using a harmless form of the herpes virus. The modified vaccine proved safer while still causing a 20-percent decline in amyloid plaque in the brain, offering new hope for developing a safe and effective vaccine.
Researchers warn that live flavivirus vaccines can recombine, resulting in new microbes with undesirable properties. The use of these vaccines requires international approval due to safety concerns, including increased virulence, disease development in compromised individuals, and birth defects.
Researchers have identified proteins that determine which mice succumb to mousepox and which do not. Strains resistant to infection produce type-1 cytokines, while susceptible ones produce type-2 cytokine IL-4. The discovery could enable better protection for humans against smallpox.
Researchers have made significant progress in developing a therapeutic vaccine for pancreatic cancer, which appears safe and stimulates immune activity. In a recent study, 12 patients with pancreatic cancer received the vaccine, resulting in no reported toxicity and positive changes in antibodies against the tumor.
Researchers at Thomas Jefferson University have made significant progress in developing a new vaccine against malignant melanoma, a potentially deadly skin cancer. The vaccine showed promise in a phase I-II study, with 8 of 10 patients developing positive responses to their own tumor cells that were chemically modified.
A phase II multicenter study evaluated a multiepitope CD8 T-cell vaccine for metastatic melanoma patients, demonstrating an immune response associated with longer survival. The vaccine showed promising results in stimulating an immune response, but no correlation was found with clinical tumor responses.
Researchers at Cedars-Sinai Medical Center have developed a new approach to boost the immune response against gliomas, a type of brain tumor. By targeting the interleukin 10 gene in dendritic cells, they can increase the production of IL-12, leading to a stronger Th1 response and enhanced immune response against cancer cells.
Researchers have developed a new vaccine strategy using live, crippled Salmonella bacteria that stimulate immunity to multiple pathogens. The vaccine protected mice 100% against lethal doses of both S. typhimurium and Listeria monocytogenes.
The NIH has awarded $20.7 million to create a safer smallpox vaccine for individuals with atopic dermatitis, a condition that makes them susceptible to serious reactions. Researchers will conduct both laboratory and clinical studies to understand the disease and develop protocols to safely vaccinate these patients.
The ADVN aims to understand immune responses in AD patients after natural exposure to skin viruses and investigate their reactions to the smallpox vaccine. The network will inform safer vaccine design, improving protection against the smallpox virus without life-threatening complications.
The temporary suspension of the hepatitis B vaccine at birth due to mercury concerns led to a significant decrease in first-day vaccination coverage. The study found that 11% of children born during the suspension were not vaccinated on their first day, resulting in an excess of 182,000 undervaccinated children by 19 months.
The Department of Defense Smallpox Vaccination Program reported over 50 cases of myopericarditis, a heart muscle inflammation, following vaccination. Most soldiers experiencing complications have recovered well with therapy, but researchers stress the need for further study to better understand potential cardiac risks.
Researchers at Brookhaven National Laboratory have deciphered the structure of botulinum toxin, shedding light on its mechanism of action. By modifying a single amino acid, scientists created an inactive form of the toxin that retains structural similarity to the active form, paving the way for potential vaccine development.
Scientists are developing a new anthrax vaccine that requires fewer shots and has fewer side effects. The study aims to improve upon the existing vaccine, which causes numerous side effects and takes 18 months to confer protection.
A new investigational anthrax vaccine is being tested in a phase II human study at Saint Louis University. The vaccine aims to provide better protection, an improved safety profile and a simpler dosing schedule.
Drs. Thal and Nitsch receive the Potamkin Prize for their groundbreaking research on effective therapies to treat and prevent Alzheimer's disease. Their work has revitalized hopes for a vaccine and slowed cognitive decline in patients.
A survey of oncologists and nurses found that while most agree to offer trial results to patients, only 62% actually do so due to concerns over potential negative effects, patient interpretation, and resource consumption. Additionally, a new study demonstrates tamoxifen's association with reduced breast density, particularly in younger...
A study found that HIV-positive US military personnel who received a smallpox vaccine between 2002-2003 showed no negative effects. The researchers suggest exempting HIV-infected individuals from vaccination during outbreaks, but consider weakened vaccines for immunocompromised people in the future.
Researchers equipped dendritic cells with genetic material from patient's tumor and PAMPs to break T-cell tolerance, enabling activation of immune system. This approach merges strengths of viral vaccines with ease of using patient's own immune system.
A recent study examined 350 adult volunteers and found that 3.6% developed harmless skin rashes after vaccination. The rashes cleared up on their own within one to three weeks without serious symptoms.
A new dental caries vaccine is being proposed as a crucial tool to prevent the spread of tooth decay, particularly in vulnerable populations. The symposium emphasizes the vaccine's potential to combat the disease and its impact on public health.
A team of scientists has successfully tested a new smallpox vaccine that shows promise as an alternative to the existing Dryvax vaccine. The MVA vaccine was found to elicit equivalent or higher immune responses in nonhuman primates, providing protection against monkeypox.
Researchers developed a topical vaccine that induces high levels of anti-ricin immune responses in mice, with 70% survival rate upon lethal challenge. The vaccine candidate offers a viable alternative delivery route for ricin poisoning treatment.
The Phase I study demonstrated a clear dose-response relationship between the amount of rPA102 administered and the subsequent immune response, with antibody titers continuing to increase after the second and third administration. The vaccine was well-tolerated, with no evidence of dose-limiting toxicity or reactogenicity at any dose.
Researchers develop vaccine that prevents tumor growth in mice, while also reversing cardiac dysfunction through gene therapy. These breakthroughs demonstrate the potential of combinatorial approaches to vaccination and gene therapy for treating neoplastic lesions and heart disease.
A new vaccine has been shown to halt HER-2/neu preneoplastic breast cancer lesions through both morphologic and gene expression data. The findings suggest a potential breakthrough in the treatment of this type of cancer, according to a recent study published in JCI Journals.
A new vaccine has shown significant improvement in 5-year progression-free survival rates for patients with renal cancer, with a 77% rate in the vaccinated group compared to 68% in the control group. The well-tolerated treatment was associated with only 12 adverse events.
The study found that the chickenpox vaccine's effectiveness decreases significantly after one year, with 97% efficacy in the first year and 84% in subsequent years. The vaccine's effectiveness was lower for children under 15 months old, with a 73% efficacy rate.
Research by Ann Bostrom reveals that people's willingness to accept vaccine risks depends on what they do and don't know. Personal experiences with adverse reactions also impact risk perception. The study highlights the need for both technical analysis and deliberation in decision-making processes.
Dr. Offit reviews scientific evidence on vaccine safety, finding no link between vaccines and weakened immune systems, allergic or autoimmune diseases, or mercury injury. The Vaccine Education Center provides up-to-date science-based information on vaccines and preventable diseases.
A phase II trial of a melanoma vaccine showed promising results, with nearly half of patients living at least five years after receiving the treatment. The vaccine's effectiveness was influenced by the dosing schedule and immune response, highlighting the importance of personalized medicine in cancer treatment.
Dr. Peter Jahrling has been recognized by the American Association for the Advancement of Science (AAAS) as a Fellow for his contributions to vaccine development and medical defense against infectious diseases. He is credited with advancing research on filovirus and poxvirus threats.
Researchers at Purdue University developed a miniature device sensitive enough to detect a single virus particle, with applications in environmental health monitoring and homeland security. The device uses a tiny cantilever that vibrates at a specific frequency when a virus particle lands on it, allowing for real-time detection.
Researchers have successfully developed a cancer vaccine using low-affinity epitopes that shows high vaccination efficiency in antitumor immunotherapy. The study, published in JCI Journals, offers promising results for the treatment of various types of cancer.
Researchers found that a peptide called LL-37 selectively kills the vaccinia virus in the smallpox vaccine, which could enable thousands of civilians or military personnel with atopic dermatitis to receive the vaccine. This breakthrough may lead to safer testing and better predict and control reactions to the vaccine.
A new study has shown that vaccinia transfer after smallpox immunization is extremely low if proper precautions are taken. The risk of transmission can be greatly reduced by keeping the vaccine site bandaged and practicing thorough hand-washing.
A meta-analysis of five published trials found that aluminium-containing vaccines were more likely to cause redness and induration in young children and local pain in older children. However, there was no evidence of serious or long-lasting side effects.
A new recombinant tuberculosis vaccine is being tested in a Phase I clinical trial in the United States, combining two proteins known to stimulate strong immune responses in humans. The vaccine aims to offer protection against pulmonary TB, the most contagious form of the disease.
Researchers found that parents who received a photo calendar of their baby's upcoming immunization dates were more likely to vaccinate their child. The study showed an 82% vaccination rate among babies whose parents received the calendars, compared to 65% for those without.
The use of rubella vaccine has increased globally, with 124 countries using it in their immunization programs by 2002. Surveillance for congenital rubella syndrome remains a concern, with incomplete reporting and estimated cases being only 0.1% of true total.
The National Vaccine Advisory Committee recommends strengthening routine vaccine supplies by increasing funds for stockpiles, supporting regulatory agencies, and improving communication. The committee also highlights the need for increased investment in vaccine manufacturing facilities and development of new vaccines to sustain supply.
A study found that nearly 750 pediatricians and family practice physicians reported a rise in vaccine concerns, with many citing short-term effects and unproven allegations. Physicians must be equipped to address these concerns and provide accurate information on vaccine safety.
A survey of 743 physicians found that parents' refusal of vaccines is becoming a growing concern, with many citing fears about short-term reactions and long-term complications. Pediatricians are more likely than family physicians to provide additional information and discuss concerns with parents.
The meningococcal vaccine is safe and effective in preventing invasive meningococcal disease, which can cause severe illness or death. Despite its value, many parents and teens are not informed about the vaccine due to limited public resources and high costs.
The incidence of pertussis among infants increased significantly between 1980 and 1999, with a 49% rise in reported cases. The majority of these cases occurred among infants under four months old, suggesting the need for improved vaccination strategies to control the spread of the disease.
Researchers at USAMRIID have developed Ebola virus-like particles (VLPs) that induce both cell-mediated and humoral immunity in mice, providing 100% protection against lethal challenge. The VLPs, resembling infectious viral particles without genetic material, offer a promising vaccine platform for Ebola and other viruses.
A new form of coronavirus was genetically altered to resemble parts of the SARS virus, then injected into rhesus macaques. The results showed strong immune responses against SARS in all immunized animals, suggesting a potential protective vaccine.
Researchers have developed a device, known as a micromechanosensor, that allows for rapid detection of botulism toxins, which can cut detection time from days to minutes. This could lead to more effective treatment and lower mortality rates among those afflicted.
A new investigational vaccine to prevent hepatitis C has been tested in humans for the first time, offering a promising breakthrough against the deadly virus. The study aimed to assess the safety and effectiveness of three different strengths of the Chiron Corporation's vaccine.
A Phase II clinical study of TP10 found that the complement inhibitor significantly reduced heart attacks and death in male patients undergoing open heart surgery. The study showed a significant decrease in composite endpoints for death, myocardial infarction, and prolonged intubation in males treated with TP10.
Researchers have found that a new vaccine can diminish symptoms of Alzheimer's disease by increasing clearance of amyloid beta protein from the brain. The study used monkeys and showed that vaccinating them with synthetic amyloid beta peptide enhanced clearance, leading to reduced plaques and improved cognitive function.
A recent study has found a link between smallpox vaccination and rare heart diseases, including pericarditis and myocarditis. Twenty-four cases of these conditions were identified among 37,876 US civilian healthcare workers who received the vaccine as part of a bioterrorism readiness program.
Researchers found that individuals vaccinated against smallpox maintained anti-smallpox antibodies for at least 60 years after vaccination. Memory B cells initially declined but then plateaued approximately ten times lower than their peak and remained stable for over 50 years.
A UK measles expert warns that major epidemics are likely to occur in the country this winter if vaccination rates do not improve rapidly. The Lancet publication cites unequivocal evidence supporting the safety of the MMR vaccine and highlights the risks associated with unvaccinated children.